The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
Abstract Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel in vitro. In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Open life sciences - 18(2023), 1 vom: 07. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Ling [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© 2023 the author(s), published by De Gruyter |
|---|
| doi: |
10.1515/biol-2022-0533 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY00900534X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY00900534X | ||
| 003 | DE-627 | ||
| 005 | 20230813133116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/biol-2022-0533 |2 doi | |
| 035 | |a (DE-627)GRUY00900534X | ||
| 035 | |a (DE-B1597)biol-2022-0533-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 100 | 1 | |a Zhou, Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 the author(s), published by De Gruyter | ||
| 520 | |a Abstract Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel in vitro. In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC. | ||
| 700 | 1 | |a Zhang, Wenchao |4 aut | |
| 700 | 1 | |a Xiang, Yi |4 aut | |
| 700 | 1 | |a Qian, Zijun |4 aut | |
| 700 | 1 | |a Zhou, Jianping |4 aut | |
| 700 | 1 | |a Ni, Lei |4 aut | |
| 700 | 1 | |a Feng, Yun |4 aut | |
| 700 | 1 | |a Gao, Beili |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open life sciences |d De Gruyter, 2015 |g 18(2023), 1 vom: 07. März |h Online-Ressource |w (DE-627)GRUY00003049X |w (DE-600)2817958-4 |w (DE-576)429286279 |x 2391-5412 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:1 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/biol-2022-0533 |z kostenfrei |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 1 |b 07 |c 03 | ||